Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Gonzalez Tome, M Isabel ^a   Amador, Jose Tomas Ramos ^b   Peña, Jose Mellado ^c   Gomez, M Luisa Navarro ^d   Conejo, Pablo Rojo ^a   Fontelos, Pablo Martin ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTHROPOMETRY; ARTICLE; BODY FAT; BONE MINERAL; CHILD; CHILD CARE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FACIAL LIPOATROPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LABORATORY TEST; LEAN BODY WEIGHT; LIPID ANALYSIS; LIPOATROPHY; LIPODYSTROPHY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD; ADIPOSE TISSUE; ADOLESCENT; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METHODOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; TREATMENT OUTCOME; VIROLOGY;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPERLIPIDEMIAS; LIPODYSTROPHY; MALE; NEVIRAPINE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 56649086855     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-144     Document Type: Article

References (31)

1. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe, AIDS 2004, 18(10):1443-1451. 10.1097/01.aids.0000131334.38172.01 15199321
2. Leonard EG McComsey GA: Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003, 22(1):77-84. 10.1097/ 00006454-200301000-00018 12544413
3. McComsey G Bhumbra N Ma JF Rathore M Alvarez A: First Pediatric Switch Study Impact of protease inhibitor substitution with efavirenz in HIV-infected children: Results of the First Pediatric Switch Study. Pediatrics 2003, 111(3):e275-281. 10.1542/peds.111.3.e275 12612284
4. Amaya RA Kozinetz CA McMeans A Schwarzwald H Kline MW: Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002, 21(5):405-410. 10.1097/00006454-200205000-00011 12150177
5. Bockhorst JL Ksseiry I Toye M Chipkin SR Stechenberg BW Fisher DJ Allen HF: Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 2003, 22(5):463-465. 10.1097/00006454-200305000-00017 12797313
6. Rojo Conejo P Ramos Amador JT Garcia Pinar L Ruano Fajardo C Sanchez Granados JM Gonzalez Tome MI Ruiz Contreras J: Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy. An Pediatr (Barc) 2004, 60(3):249-253. 10.1157/13058075 14987516
7. European Paediatric Lipodystrophy Group: Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004, 18(10):1443-1451. 10.1097/01.aids.0000131334.38172.01 15199321
8. McComsey GA Leonard E: Metabolic complications of HIV therapy in children. AIDS 18(13):1753-1768. 2004 Sep 3 10.1097/ 00002030-200409030-00004 15316336
9. Carr A Samaras K Burton S Law M Freund J Chisholm DJ Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. AIDS 1998, 12:f51-58. 10.1097/ 00002030-199807000-00003 9619798
10. Tsiodras S Mantzoros C Hammer S Samore M: Effect of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: A 5-year cohort study. Arch Intern med 2000, 160:2050-2056. 10.1001/archinte.160.13.2050 10888979
11. Periard D Telenti A Sudre P Cheseaux JJ Halfon P Reymond MJ Marcovina SM Glauser MP Nicod P Darioli R Mooser V: Atherogenic dyslipemia in HIV infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation 1999, 100:700-705. 10449690
12. Vigano A Mora S Testolin C Beccio S Schneider L Bricalli D Vanzulli A Manzoni P Brambilla P: Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003, 32(5):482-489. 10.1097/00126334-200304150-00003 12679698
13. Martinez E Arnaiz JA Podzamczer D Dalmau D Ribera E Domingo P Knobel H Riera M Pedrol E Force L Llibre JM Segura F Richart C Cortes C Javaloyas M Aranda M Cruceta A de Lazzari E Gatell JM: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. N Engl J Med 2003, 349(11):1036-1046. 10.1056/ NEJMoa021589 12968087
14. Clotet B Valk van der M Negredo E Reiss P: Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):79-84.
15. Negredo E Cruz L Paredes R Ruiz L Fumaz CR Bonjoch A Gel S Tuldra A Balague M Johnston S Arno A Jou A Tural C Sirera G Romeu J Clotet B: Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002, 34(4):504-510. 10.1086/324629 11797178
16. Negredo E Ribalta J Paredes R Ferre R Sirera G Ruiz L Salazar J Reiss P Masana L Clotet B: Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002, 16(10):1383-1389. 10.1097/ 00002030-200207050-00010 12131215
17. Ruiz L Negredo E Domingo P Paredes R Francia E Balague M Gel S Bonjoch A Fumaz CR Johnston S Romeu J Lange J Clotet B: Spanish Lipodystrophy Group Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001, 27(3):229-236. 11464141
18. Fisac C Fumero E Crespo M Roson B Ferrer E Virgili N Ribera E Gatell JM Podzamczer D: Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005, 19:917-925. 10.1097/01.aids.0000171405.46113.bf 15905672
19. Tebas P Yarasheski K Henry K Claxton S Kane E Bordenave B Klebert M Powderly WG: Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retrovirus 2004, 20(6):589-594. 10.1089/0889222041217374
20. Zachetta JR Plotkin H Alvarez Figueira ML: Bone mass in children: Normative values for the 2-20 years old population. Bone 1995, 16(Suppl):393-399.
21. Genant HK Cooper C Poor G Reid I Ehrlich G Kanis J Nordin BE Barret-Connor E Black D Bonjour JP Dawson-Hughes B Delmas PD Dequeker J Ragi Eis S Gennari C Jhnell O Johnston CC Lau EM Liberman UA Lindsay R Martin TJ Masri B Mautalen CA Meunier PJ Khaltaev N: Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999, 10(4):259-264. 10.1007/s001980050224 10692972
22. Tanner JM: Grow and adolescence Oxford. Blackwell Scientific publication 2 1962
23. Melvin AJ Lennon S Mohan KM Purnell JQ: Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001, 17(12): 1117-1123. 10.1089/ 088922201316912727 11522181
24. Castelli-Gattinara G Amicosante M Palam P: 3-NRTI HAART simplification in children is effective in maintaining virological and immunological control after 108 weeks. 13th Conference on Retrovirus and Opportunistic Infections. Denver. February 2006. (Abstract 18)
25. Kumar PN Rodriguez-French A Thompson MA: Prospective study of hyperlipidemia in antiretroviral therapy-naive subjects taking abacavir/ Combivir, Combivir/nelfinavir, or lamivudine/stavudine/nelfinavir(GSK Protocol ESS40002). Antiviral Ther 2001, 6(Suppl 4):19-20.
26. Saint-Marc T Touraine JL: The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999, 13(15):2188-2189. 10.1097/ 00002030-199910220-00035 10546885
27. Moyle GJ Baldwin C Langroudi B Mandalia S Gazzard BG: A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003, 33(1):22-28. 12792351
28. Carr A Workman C Smith DE Hoy J Hudson J Doong N Martin A Amin J Freund J Law M Cooper DA: Abacavir substitution for nucleoside analogs in patients with lipoatrophy: A randomised trial. JAMA 2002, 288:207-215. 10.1001/jama.288.2.207 12095385
29. Scevola D Di Matteo A Lanzarini P Uberti F Scevola S Bernini V Spoladore G Faga A: Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003, 17(Suppl 1):S123-129. 12870538
30. Clumeck N Goebel F Rozenbaum W Gerstoft J Staszewski S Montaner J Johnson M Gazzard B Stone C Athisegaran R Moore S: CNA30017 Study Team Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001, 15(12):1517-1526. 10.1097/00002030-200108170-00009 11504984
31. Wanke CA: Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999, 13(11):1287-1293. 10.1097/00002030-199907300-00004 10449280